IntelliCyt Corporation, an Albuquerque, New Mexico-based provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, completed an $8m financing round.
The round was led by new investor Arboretum Ventures with participation from existing investors Prolog Ventures, Verge Fund, and New Mexico Community Capital. In conjunction with the financing, Tim Petersen and George Dunbar of Arboretum Ventures will join IntelliCyt’s Board of Directors.
The company intends to use the funds to expand their commercial efforts globally, grow manufacturing capacity, and expand their suite of reagent kits.
Founded in 2006 and led by R. Terry Dunlay, President and CEO, IntelliCyt develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing
(See here the products).